American Epilepsy Society Annual Meeting (AES)

Uliel-Sibony discussed her and her colleagues' study of CBD, and its findings on when tolerance develops for which patient population.

The professor and vice chair of the neurology department at UCLA discussed the new VNS, RNS and DBS CPT codes for 2019.

The Clinical Fellow in Neurophysiology and Epilepsy at Massachusetts General Hospital spoke about the implications of this assessment of SUDEP.

The attending neurologist at Brigham and Women's Hospital spoke about how seizure frequency during pregnancy and postpartum varies by epilepsy type.

The Director of the cEEG and Epilepsy Consult Service at the Cleveland Clinic Epilepsy Center spoke about when clinicians should initiate and stop anti-seizure medications.

The Director of the cEEG and Epilepsy Consult Service at the Cleveland Clinic Epilepsy Center spoke about the cautious for physicians treating patients with acute symptomatic seizures.

The pediatric epileptologist at Nicklaus Children’s Hospital spoke about the long-term seizure freedom data that showed that perampanel was associated with a sustained or increased improvement in seizure control.

The professor of pediatrics at Tel Aviv University explained what has been fleshed out by the research and shared his opinion on cannabidiol’s use.

The head of the Children’s Brain Dynamics Laboratory at Boston Children’s Hospital discussed the HOPE project and its goals moving forward.

The pediatric epileptologist and adjunct professor of pediatrics at the University of Calgary spoke about how drastically things have changed surrounding the patient-physician conversation about SUDEP.

The Director of the Cleveland Clinic Epilepsy Center spoke about how important it is for clinicians to not select the wrong patients for deep brain stimulation.

The epileptologist at the University of Pennsylvania spoke about the multiple options for patients with epilepsy and the need for a better understanding of choosing from the options.

The director of the epilepsy center at Cleveland Clinic spoke about the process that leads to the selection of candidacy for deep brain stimulation.

The director of the Epilepsy Center at Children's Health spoke about the findings of the clinical screening program, and how depression is often overlooked in patients with epilepsy.

The chief medical officer at SK Life Science discussed what makes cenobamate unique, as well as what current studies have discovered.

The pediatric psychologist at Children’s Medical Center discussed what her team does to assess patients in the clinic when something comes up as a result of a patient’s screening.

The Director of the Epilepsy Division at Mayo Clinic in Phoenix discussed the issue of driving when withdrawing patients off seizure medication either because of treatment, remission or surgical intervention.

The section chief of pediatric neurology at Nationwide Children’s Hospital discussed cannabidiol's potential in the Lennox-Gastaut syndrome space.

The Director of the Stanford Epilepsy Center discussed the work that’s left to be done in the field of epilepsy.

The instructor in neurology at Beth Israel Deaconess Medical Center spoke about what clinicians can do right now to mitigate the risk of SUDEP and the myriad of options for them to utilize.

The SVP and chief strategy and development officer at Aquestive Therapeutics discussed the hope to provide both patients and providers with a more favorable, and still efficacious, option for seizure clusters.

Recent data has shown that a start low, go slow approach with cenobamate may mitigate the risk of drug reaction with eosinophilia and systemic symptoms syndrome.

The Director of the UCLA Seizure Disorder Center explained the importance of referring patients with seizures to epilepsy centers.

The largest and longest prospective neuromodulation trial in the field of epilepsy showed about a 75% response rate with patients achieving at least a 50% reduction in seizures.

The Director of the Stanford Epilepsy Center discussed the current activities of epileptologists and considered how this might change in the near future, given advancing technology.

The associate professor of neurology at the University of Rochester shared some of her advice for treating patients with epilepsy and focusing on the patient.

The director of the Epilepsy Program at Children’s Hospital of Philadelphia spoke about the long-awaited advancement brought on by cannabidiol for Dravet syndrome.

This novel dosage form of diazepam had comparable times to maximal concentration in both 2-hour and 4-hour timeframes.

The section chief of pediatric neurology at Nationwide Children’s Hospital and an associate professor of clinical pediatrics and neurology at The Ohio State University College of Medicine spoke about what the findings mean for patients.

The recently approved therapy remained generally well tolerated and improvements in overall condition in Subject/Caregiver Global Impression of Change scores.